Furthermore, GPRC5A together with FXYD domain-containing ion transport regulator 3 (FXYD3) and PYCARD have been reported as potential predictors of pathological grading of breast cancer and might benefit the management of clinical treatments [84]. This evidence concerns the gene FXYD3 and breast carcinoma.